Background {#Sec1}
==========

Retinopathy of prematurity (ROP) refers to the developmental disorder of the retina in premature infants and is one of the most serious and most dangerous complications in premature infants.

Embryonic retinal arteries start to grow in the third month of pregnancy and their development ends at birth. Therefore, the stages of evolution of the eye are defective in premature infants, and the growth of the vessels is either stopped or unusual, and ultimately, the vessels become very fragile, which can lead to visual impairment in severe cases \[[@CR1]\].

Despite considerable progress made in the treatment of ROP, it is still a common cause of reduced vision in children in developed countries, and its prevalence is increasing \[[@CR2]--[@CR4]\]. This is a preventable disease and responds to treatments appropriately if diagnosed at early stages, but in case of delayed diagnosis and treatment, it may lead to blindness \[[@CR5]\].

The first incidences of ROP were reported in the 1940s and 1950s, mainly as a result of the use of supplemental oxygen without supervision (first epidemic). Although the survival of premature infants improved in the following decades, and despite improved monitoring methods for oxygen supplements, ROP emerged with an increasing incidence (second epidemic) \[[@CR6]\]. Over the past decade, the increasing incidence of ROP blindness has been recorded in low-income countries. Studies show that ROP is the leading cause of blindness in China, Southeast Asia, South America, Latin America, and Eastern Europe, especially in urban centers of newly industrialized countries, and this is referred to as the "third epidemic" \[[@CR7]\].

ROP is a multifactorial disease and the most important risk factors are preterm delivery, especially before the 32nd week of gestation and birth weight less than 1500 g. Apnea, intraventricular hemorrhage, various maternal factors (diabetes, preeclampsia, mother's smoking), respiratory disorders, infection, vitamin E deficiency, heart disease, increased blood carbon dioxide, increased oxygen (O~2~) consumption, decreased PH, decreased blood O2, bradycardia, transfusion, amount of received oxygen and duration of ventilation are other risk factors for ROP \[[@CR8]--[@CR10]\].

The prevalence of ROP in different regions of Iran is different and its prevalence is reported to be 1--70% in different regions \[[@CR11]--[@CR14]\]. Considering the abovementioned issues and the importance of the subject, as well as the diversity of reports in Iranian studies, it is necessary to carry out more extensive and precise studies. Meta-analysis is a method that collects and analyzes multiple research data with a common purpose to provide a reliable estimate of the impact of some interventions or observations in medicine \[[@CR15], [@CR16]\]. Obviously, the sample size in meta-analysis becomes larger by collecting data from several studies and therefore the range of changes and probabilities will be reduced; therefore, the significance of statistical results increases \[[@CR16], [@CR17]\]. This study aims to determine the incidence and risk factors for ROP in Iran.

Methods {#Sec2}
=======

Study protocol {#Sec3}
--------------

This review article was conducted based on the preferred reporting items for systematic review and meta-analysis (PRISMA) protocols \[[@CR16]\]. The study was conducted in five stages: design and search strategy, a collection of articles and their systematic review, evaluation of inclusion and exclusion criteria, qualitative evaluation and statistical analysis of data. To avoid bias in the study, each of the above steps was carried out by two researchers independently. In case of differences in the results obtained by the two researchers, a third researcher intervened to reach an agreement.

Search strategy {#Sec4}
---------------

To find literature about ROP in Iran, a comprehensive search was done using the terms (Retinopathy of Prematurity \[MeSH\]) AND ("Incidence" \[MeSH\] OR "Epidemiology" \[MeSH\]), OR ("Prevalence" \[MeSH\]) AND ("Iran" \[MeSH\]) in 7 international databases including PubMed, Ovid, Science Direct, EMBASE, Web of Science, CINAHL, EBSCO, and 5 national databases including Magiran, Iranmedex, SID, Medlib, IranDoc, as well as Google Scholar search engine until May 2017. References to all relevant articles were reviewed. Due to the inability of Iranian databases to search using Boolean operators (AND, OR and NOT), searches on these databases were only performed using the keywords.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Articles with the following characteristics were chosen for meta-analysis: 1. Original research papers published either in Persian or English; 2. Medical dissertations; 3. Review of the prevalence or risk factors for ROP. The exclusion criteria were: 1. Non-random sample for estimating the prevalence; 2. Being irrelevant to the topic; 3. Congress papers; 4. Sample size other than premature infants; 5. Non-Iranian studies; 6. Review articles, case reports, editorials; 7. Duplicate studies and 8. Low-quality studies.

ROP detection criteria {#Sec6}
----------------------

ROP was diagnosed by an expert through examination of retinas of infants using indirect ophthalmoscope.

Selection of studies {#Sec7}
--------------------

First, all related articles (articles with affiliations containing Iranian authors) were collected and a list of titles was prepared at the end of the search and removal of duplicates. After blinding the specifications of the articles by on researcher (Milad Azami), including the name of the journal and the name of the author, the full text of the articles was presented to the researchers. Each article was studied by two researchers independently (Gholamreza Badfar, Afsar Dastjani Farahani). If the article was rejected, the reason for this rejection was mentioned. In case of disagreement between the two authors, the article was judged by the team of researchers.

Quality of studies {#Sec8}
------------------

Using the standard modified Newcastle Ottawa Scale (NOS) checklist \[[@CR18]\], which included 8 sections. Thus, the minimum and maximum score available on this checklist were 0 and 8, respectively. Accordingly, the studies were divided into three categories: 1. low quality with a score less than 5; 2. moderate quality with a score of 5--6; and 3. high quality with a score of 7--8. Finally, the moderate to high quality studies were selected for the meta-analysis stage.

Data extraction {#Sec9}
---------------

The raw data of the prepared articles were extracted using a premade checklist. The checklist includes the name of the authors, published year the year of study, the location of the study, the study design, quality score, sample size, the prevalence of ROP, the ROP detection criteria, the prevalence of ROP based on gender (ROP) and ROP risk factors.

Statistical analysis {#Sec10}
--------------------

In each study, the prevalence of ROP was considered as the probability of binomial distribution. To evaluate the heterogeneity of the studies, Cochran's Q test and I^2^ index were used \[[@CR19]\]. There are three categories for the I^2^ index: heterogeneity lower than 25%, heterogeneity between 25% and 75% and heterogeneity more than 75%. Considering the heterogeneity of the studies, a random effects model was used to combine ROP prevalence. For ROP risk factors, the fixed effects model and the random effects model were used, respectively in the case of low heterogeneity and high heterogeneity in the meta-analysis \[[@CR20], [@CR21]\]. Sensitivity analysis was performed to identify the influence of a single study on the combined result incidence or any risk factors (with ≥ 7 studies). In order to identify the cause of heterogeneity of ROP prevalence, sub-groups analysis of ROP were carried out based on geographical region, province and quality of studies, while the meta-regression model (method of moments) was carried out based on the year of studies \[[@CR22]\]. Egger and Begg's tests were used to identify publications bias. Data analysis was performed using Comprehensive Meta-Analysis Software Version 2 and the significance level in the tests was considered to be lower than 0.05.

Results {#Sec11}
=======

Search results and characteristics {#Sec12}
----------------------------------

In the initial search, 452 studies were found to be related to the topic. Two independent researchers reviewed the title and the abstract. If the title or abstract was likely to be related to the topic, the full text was reviewed. After reviewing the full text of 74 relevant articles, 30 articles were omitted due to lacking the necessary criteria and finally 44 qualified studies entered the qualitative assessment stage (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} shows the characteristics of each study.Fig. 1PRISMA flowchart for the selection of studiesTable 1Summary of demographic characteristics in studies into a meta-analysisRef.First author, Published YearYear of studyGA^a^ (week)BW^b^ (gr)PlaceSample sizePrevalence (%)QualityAllNon-ROP^c^ROP\[[@CR11]\]Naderian Gh, 20112009\< 34And ≤ 1800Isfahan100712929Moderate\[[@CR11]\]Naderian Gh(1), 20112009\< 34And ≤ 1800Isfahan100584242Moderate\[[@CR12], [@CR13]\]Mostafa Gharebagh M, 20122008\< 34--Tabriz714130High\[[@CR14]\]Nakhshab M, 20162014\< 30 or \< 34^d^--Sari1461222416.44High\[[@CR52]\]Naderian G, 2009200225--34And 600--1800Isfahan79666213416.8Moderate\[[@CR53]\]Hosseini H, 20092006\< 34--Shiraz10241004201.95High\[[@CR54]\]Karkhaneh R, 20052000≤ 37And ≤ 2500Tehran1851622312.4High\[[@CR55]\]Naderian G, 20102003----Isfahan60449810617.5High\[[@CR56]\]Mansouri M, 20072004≤ 32And ≤ 1500Tehran1471034429.9High\[[@CR57]\]Nakshab M, 20032001--≤ 2500Sari6860811.7High\[[@CR58]\]Daraie G, 20162008\< 37Or \< 2000Semnan27026731.1Moderate\[[@CR59]\]Fayazi A,20092005\< 32Or \< 1500 or 1500--2500^\*^Tabriz399370297.26Moderate\[[@CR60]\]Sadeghi K, 20082006\< 36And \< 2000Tabriz1501242617.3Moderate\[[@CR61]\]Ebrahimiadib N, 20162011\< 37Or \< 3000Tehran1896132657030.06Moderate\[[@CR62]\]Ghaseminejad A, 20112006≤ 36And ≤ 2500Kerman83592429High\[[@CR63]\]Khatami F, 20082000\< 34Or \< 2000Mashhad50361428Moderate\[[@CR64]\]Sabzehei MK, 20132007--\< 1500Tehran4143437117.14Moderate\[[@CR65]\]Saeidi R, 20092005≤ 32Or \< 1500Mashhad474348.5Moderate\[[@CR66]\]Azin Far B, 20052001\< 29And \< 1500Babol100564444High\[[@CR67]\]Karkhanehyousefi N, 20092009----Babol100613939Moderate\[[@CR68]\]Ebrahimzadeh A, 20092003----Tehran134387446934.9High\[[@CR69]\]Mirzaee SA, 20102008--\< 2000Tehran745024324Moderate\[[@CR70]\]Mousavi Z, 2009200124--36And 600--2900Tehran79754025732.24Moderate\[[@CR71]\]Fouladinejad M, 20092004≤ 34--Gorgan898455.6High\[[@CR72]\]Mousavi S, 2008200124--36And 600--2800Tehran69347421931.6Moderate\[[@CR73]\]Sadeghzadeh M, 20162001--450--3000Zanjan787711.2Moderate\[[@CR74]\]Bayat-Mokhtari M, 20102006--\<  1500 Or 1500--2000\*Shiraz1991158442High\[[@CR75]\]Karkhaneh R, 20011997\< 37Or \< 2500Tehran15014196High\[[@CR76]\]Babaei H, 20122009--≤ 1500Kermanshah84731113.1Moderate\[[@CR77]\]Abrishami M, 20132006\<  32--Mashhad122903226.2High\[[@CR78]\]Riazi-Esfahani M, 20082002≤ 37And ≤ 2500Tehran1651254024.24Moderate\[[@CR79]\]Alizadeh Y, 20152005≤ 36And ≤ 2500Rasht3102466420.6High\[[@CR80]\]Mousavi SZ, 20102003----Tehran60541519031.4Moderate\[[@CR81]\]Mousavi Z, 20102003----Tehran105367338036.1High\[[@CR82]\]Feghhi M, 20122006\< 32And ≤ 2000Ahvaz57639318332High\[[@CR83]\]Afarid M, 20122006≤ 32And ≤ 2000Shiraz78749429337.2Moderate\[[@CR84]\]Ahmadpourkacho M, 20142009\< 28And \< 1500 or 1500--2000\*Babol2567618070.31High\[[@CR85]\]AhmadpourKacho M, 20142007\< 34And \< 2000Babol155857045.2Moderate\[[@CR86]\]Rasoulinejad SA, 20162007\< 36And \< 2500Babol68037430645High\[[@CR87]\]Karkhaneh R, 20082003\<  37--Tehran95362432934.5High\[[@CR88]\]Khalesi N, 20152013----Tehran1206060Moderate\[[@CR89]\]Ebrahim M, 20102004\<  37--Babol1731403319.1High\[[@CR90]\]Roohipoor R, 20162012≤ 37And ≤ 3000Tehran193213625703High\[[@CR91]\]Mansouri M, 20162013\<  34Or \< 2000Sanandaj4742510.6High^a^Gestational age; ^b^Birth weight; ^c^Retinopathy of prematurity; ^d^With unstable condition

Prevalence {#Sec13}
----------

Reviewing 42 studies with a total sample size of 18,000 premature infants, the prevalence of ROP in Iran was estimated to be 23.5% (95% CI: 20.4--26.8). The lowest and highest prevalence was related to the studies in Semnan (2008) (1.1%) (58) and in Babol (2009) (70.3%) (84), respectively (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2The prevalence of retinopathy of prematurity in Iran. Random effects model

Sensitivity analysis and cumulative analysis for ROP {#Sec14}
----------------------------------------------------

The sensitivity analysis of the prevalence or risk factors of ROP and its 95% confidence interval (CI) was estimated simultaneously regardless of one study and the results showed that the incidence or risk factors of ROP were not significantly changed before and after the deletion of each study. (Fig. [3a](#Fig3){ref-type="fig"}). Cumulative analysis for incidence of ROP based on the year of publication is shown in Fig. [3b](#Fig3){ref-type="fig"}.Fig. 3Sensitivity analysis (**a**) and cumulative analysis based on the year of publication (**b**) for prevalence of retinopathy of prematurity in Iran. Random effects model

Subgroup analysis of ROP prevalence based on geographic region {#Sec15}
--------------------------------------------------------------

In the reviewed studies, 2, 4, 12, 4, and 20 studies were related to the West, East, North, South, and Center of Iran, respectively. The prevalence of ROP in the five regions of Iran is shown in Table [2](#Tab2){ref-type="table"} and the lowest incidence of ROP was in west of Iran (12.3% \[95% CI: 7.6--19.1\]), while the highest prevalence was related to the center of Iran (24.9% \[95% CI: 21.8--28.4\]) (Table [2](#Tab2){ref-type="table"}).Table 2The prevalence of ROP based on region, gender, provinces and quality of studiesVariableStudies (N^a^)Sample (N)Heterogeneity95% CI^b^Prevalence (%)I^2^*P*-ValueRegionCenter2012,35593.65\< 0.00121.8 to 28.424.9East430257.790.0717 to 3324.1North12262697.09\< 0.00115.9 to 37.125South4258698.60\< 0.0019.2 to 37.120.5West213100.677.6 to 19.112.3Test for subgroup differences: Q = 9.67, df(Q) = 4, *P* = 0.046GenderBoys11146792.65\< 0.00111.9 to 28.518.9Girls11118485.02\< 0.00112.8 to 25.418.3Rate ratio of boys to girls: OR^c^ = 1.07(0.86 to 1.33, *P* = 0.501)ProvincesKhozestan15760--28.3 to 35.932Mazandaran8167895.77\< 0.00123.5 to 48.234.8Isfahan4160092.48\< 0.00116.5 to 3524.6Golestan1890--2.3 to 12.85.6Kerman1830--20.3 to 39.629Kermanshah3840--7.4 to 22.113.1Razavi Khorasan321967.890.04412.4 to 34.221.3Guilan13100--16.5 to 25.520.9Kurdistan1470--4.5 to 23.110.6Semnan12700--0.4 to 3.41.1Fars3201099.09\< 0.0014 to 50.817.2East Azarbaijan254991.320.0014.6 to 2511.3Tehran1410,40791.32\< 0.00125.1 to 3128Zanjan1780--0.2 to 8.51.2Test for subgroup differences: Q = 97.59, df(Q) = 13, *P* \< 0.001QualityMedium20776063.68\< 0.00116.6 to 28.023.5High2210,24096.65\< 0.00119.1 to 28.723.5Test for subgroup differences: Q = 0, df(Q) = 1, *P* = 0.995^a^Number^b^Confidence interval

Subgroup analysis of ROP prevalence based on province {#Sec16}
-----------------------------------------------------

Table [2](#Tab2){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"} show the prevalence of ROP based on Iran's provinces. The highest prevalence was in provinces of Mazandaran (34.8%) and Khuzestan (32%), and the lowest prevalence was in the provinces of Semnan (1.1%) and Zanjan (1.2%).Fig. 4Geographical distribution of retinopathy of prematurity in Iran

Subgroup analysis of ROP prevalence based on the quality of studies {#Sec17}
-------------------------------------------------------------------

The prevalence of ROP in moderate and high-quality studies was 23.5% (95% CI: 16.6--28.0) and 23.5% (95% CI: 19.1--28.7), respectively, and the difference was not statistically significant (*p* = 0.995) (Table [2](#Tab2){ref-type="table"}).

The prevalence of ROP based on gender {#Sec18}
-------------------------------------

The prevalence of ROP in girls and boys premature infants was 18.3% (95% CI: 12.8--25.4) and 18.9% (95% CI: 11.9--28.5), respectively. Their difference was not statistically significant (*P* = 0.501) (Table [2](#Tab2){ref-type="table"}).

The prevalence of ROP based on stage {#Sec19}
------------------------------------

The prevalence of stages 1, 2, 3, 4 and 5 were reported in 10, eight, nine, five, and five studies, respectively. Fig. [5](#Fig5){ref-type="fig"} shows the prevalence of ROP at different stages. The prevalence of stages 1, 2, 3, 4 and 5 was 7.9% (95% CI: 5.3--11.5), 9.7% (95% CI: 6.1--15.3), 2.8% (95% CI: 1.6--4.9), 2.9% (95% CI: 1.9--4.5), and 3.6% (95% CI: 2.4--5.2), respectively.Fig. 5The prevalence of stages I (**a**), II (**b**), III (**c**), IV (**d**), V (**e**) retinopathy of prematurity. Random effects model

Meta-regression {#Sec20}
---------------

Meta-regression model in Fig. [6](#Fig6){ref-type="fig"} shows that the incidence of ROP is increasing according to the year of study, and this relationship is not statistically significant (meta-regression coefficient: 0.034, 95% CI -0.016 to 0.085, *P* = 0.181).Fig. 6Meta-regression of ROP prevalence based on years of studies

Publication bias {#Sec21}
----------------

The significance level of publication bias in the reviewed studies was 0.003 and 0.002 according to Egger and Begg's tests, respectively, which is shown in Fig. [7](#Fig7){ref-type="fig"}.Fig. 7Publication bias in the studies

ROP risk factors {#Sec22}
----------------

The meta-analysis results of evaluating the risk factors of ROP are shown in Table [3](#Tab3){ref-type="table"}. ROP risk factors include certain variables such as continuous positive pressure (CPAP) (*P* = 0.023), the prevalence of blood transfusion (*P* = 0.001), septicemia (*P* = 0.021), weight \< 1000 g (*P* \< 0.001), weight \<  1500 g (*P* \< 0.0001), frequency of phototherapy (*P* \< 0.0001), the frequency of oxygen therapy (*P* = 0.049), apnea (*P* = 00.2), intraventricular hemorrhage (IVH) (*P* = 0.005), respiratory distress syndrome (RDS) (*P* = 0.036), gestational age (GA) ≤ 28 W(week) (*P* \< 0.001), GA ≤32 W (*P* \< 0.001), saturation over 50% (*P* \< 0.001), mean GA (*P* \< 0.001), mean weight (*P* \< 0.0001), oxygen therapy duration (*P* \< 0.001) and phototherapy duration (*P* \< 0.0001); however, preeclampsia significantly decreases the prevalence of ROP (*P* = 0.014).Table 3Risk factor for retinopathy of prematurity in IranVariablesStudies(*N*^a^)Sample (*N*)HeterogeneityOR (95%CI^b^)*P*-ValueModel in Meta-analysisCaseControlI^2^*P*-ValueTwin birth4804186846.970.1291.62 (0.94 to 2.81)0.081Random^c^Mechanical ventilation61131249373.350.0021.81 (0.80 to 1.73)0.39RandomContinuous positive pressure ventilation26213164.110.0953.97 (1.21 to 13.01)0.023RandomBlood transfusion (N)161820416791.34\< 0.0012.38 (1.43 to 3.94)0.001RandomSepticemia111327296580.75\< 0.0011.96 (1.10 to 3.48)0.021RandomBirth weight \< 1000 g9573209359.650.0114.16 (2.35 to 7.35)\< 0.001RandomBirth weight \< 1500 g10559198443.340.0693.74 (2.54 to 5.49)\< 0.001RandomPhototherapy (N)111380335580.69\< 0.0011.50 (1.00 to 2.27)0.049RandomOxygen therapy (N)14726312487.39\< 0.0013.06 (1.29 to 7.27)0.011RandomNeed for resuscitation25621286.500.0065.01 (0.18 to 135.71)0.338RandomApnea311449272.080.0284.41 (1.70 to 11.40)0.002RandomCongenital heart disease25024667.290.082.13 (0.10 to 45.62)0.626RandomInter-ventricular hemorrhage111223317876.36\< 0.0012.24 (1.2 to 3.95)0.005RandomAcidosis313229662.620.0692.56 (0.81 to 8.06)0.106RandomCesarean section437583047.880.1241.08 (0.53 to 2.18)0.82RandomPreeclampsia210823700.820.12 (0.02 to 0.65)0.014Fixed^d^Respiratory distress syndrome112039261880.13\< 0.0011.64 (1.03 to 2.61)0.036RandomSaturation above 50%411865630.300.238.35 (3.14 to 22.18)\< 0.001RandomNormal Vaginal Delivery437583046.630.1321.01 (0.50 to 2.02)0.969RandomMultiple pregnancy61199251840.200.1370.92 (0.73 to 1.16)0.517RandomGestational age ≤ 286551144075.88\< 0.0015.20 (2.31 to 11.73)\< 0.001RandomGestational age ≤ 329689188564.840.0047.88 (4.62 to 13.46)\< 0.001RandomBirth weight (gr)71495289397.30\< 0.0010.98 (0.97 to 0.99)\< 0.001RandomGestational age (week)71495289384.20\< 0.0010.67 (0.59 to 0.770)\< 0.001RandomVariablesStudies(*N*^a^)Sample (*N*)HeterogeneityMean Difference (95% CI^b^)*P*-ValueCaseControlI^2^*P*-ValueGestational age (weeks)181835412694.53\< 0.0012.08(1.50 to 2.66)\< 0.001RandomBirth weight (gr)191782451995.94\< 0.001305.39(236.09 to 374.69)\< 0.001RandomOxygen therapy (day)111399321496.04\< 0.001−4.36(−6.09 to −2.63)\< 0.001RandomPhototherapy (days)47830883.80\< 0.001−2.08(−3.81 to −0.35)\< 0.001RandomApgar score in the first minute317421663.300.661.07(0.45 to 1.68)0.001RandomApgar score36427276.340.0150.43(−0.25 to −1.13)0.21RandomMechanical ventilation (days)211415488.810.003−4.53(−9.17 to 0.10)0.55RandomBilirubin (mg/di)3541867.700.33−0.27(−1.40 to 0.86)0.63RandomBlood transfusion (duration)29815100.98−0.69(−0.96 to − 0.42)\< 0.001Fixedclinical risk index for babies216125058.840.11−0.62(− 1.40 to 0.16)0.11Random^a^Number^b^Confidence interval^c^Random effects model^d^Fixed effects model

Discussion {#Sec23}
==========

The present study is the first systematic and meta-analytic review on the prevalence and risk factors of ROP in Iran. The results of this meta-analysis showed that the prevalence of ROP in 18,000 Iranian premature infants was 23.5%, and the prevalence for stages 1, 2, 3, 4 and 5 was 7.9%, 9.7%, 2.8%, 2.9% and 3.6%, respectively. In this study, the level of heterogeneity was high for ROP studies (95.6%). The results of the subgroup analysis showed that geographic regions and the provinces could be a cause of high heterogeneity. However, this difference can be a reflection of studies conducted on different samples based on the GA or neonatal weight.

ROP is still a major cause of potentially preventable blindness around the world \[[@CR23]\]. According to guidelines published by the American Academy of Ophthalmology, the American Academy of Children, and the American Association for Ophthalmology for Children and Strabismus for ROP screening, infants weighing less than 1500 g or GA ≤ 30 weeks, and infants weighing between 1500 and 2000 g or GA \> 30 weeks with an unstable clinical course should receive dilated ophthalmoscopy examinations for ROP \[[@CR24]\].

The prevalence of ROP in various studies is mainly due to differences in mean GA and birth weight of infants in each study. Based on GA, the prevalence of ROP significantly decreases from 77.9% in GA 24--25 to 1.1% in GA 30--31, which indicates the direct role of GA in ROP incidence. These results are completely consistent with the data published in other literature \[[@CR25]--[@CR31]\]. Moreover, in a meta-analysis study in Iran, the prevalence of prematurity was reported to be 9.2% (95% CI: 7.6--10.7) \[[@CR32]\]. Therefore, the high prevalence of ROP in Iran (23.5%) can be explained by the high prevalence of prematurity.

In a study by Tabarez-Carvajal et al. among 3018 premature infants, the incidence of stages 1, 2, 3, 4, and 5 was reported to be 8.34%, 8.78%, 1.9%, 0.03%, and 0.30%, respectively \[[@CR33]\]. In another study by Abdel HA et al., the prevalence of ROP stage 1 was 10.4%, stage 2 was 5.2% and stage 3 was 3.45%, and none of the infants had ROP at stages 4 or 5 \[[@CR34]\]. But in the present study, the prevalence of ROP stages 4 and 5 was higher.

ROP is a multi-factorial disease, and in the present study, the strongest risk factor for ROP was prematurity and low birth weight. Most studies have demonstrated that prematurity and low birth weight are the strongest predictive factors of ROP, which indicates the crucial role of factors associated with the progression of the ROP disease \[[@CR35]--[@CR45]\].

After low birth weight and prematurity, exposure to oxygen for a long period and saturation over 50% were the most important risk factors for ROP in this study, which was consistent with the results of many other studies \[[@CR42]--[@CR47]\]. Due to inadequate antioxidant defense system, premature infants are not evolved to live in an oxygen-rich ectopic environment \[[@CR48], [@CR49]\]. Oxidative stress is the result of various organs' exposure to free radicals of oxygen after being exposed to high concentrations of oxygen, which can lead to the progression of many pathogens such as ROP, necrotizing enterocolitis, IVH, bronchopulmonary dysplasia, and periventricular leukomalacia \[[@CR50], [@CR51]\].

In this study, other significant relationships with ROP were also found, including frequency and duration of blood transfusion, phototherapy, septicemia, apnea, IVH, and RDS. The comparison between the risk factors in our study and other reports is shown in Table [4](#Tab4){ref-type="table"}.Table 4Risk factor for retinopathy of prematurity in other studiesStudy detailsGA (weeks)BW (gr)Risk factorsReyes et al., 2017. Oman \[[@CR46]\]\< 32\< 1500low BW, low GA, duration of invasive ventilation, duration of oxygen therapy, duration of nasal CPAP, late onset clinical or proven sepsisShah et al., 2005 Singapore \[[@CR40]\]\< 32\< 1500Preeclampsia, low BW, prolonged duration of ventilation, pulmonary hemorrhage and CPAPYau et al., 2016, China \[[@CR45]\]\< 32 and \> 32\< 1500low GA, low BW, preeclampsia, gestational diabetes mellitus, inotrope use, postnatal hypotension, apgar score (1 min, 5 min and 10 min), respiratory distress syndrome, bronchopulmonary dysplasia, invasive mechanical ventilation, surfactant use, oxygen supplement, patent ductus arteriosus, thrombocytopenia, blood transfusion, anemia, NSAID use, sepsisAbdel HA et al., 2012, Egypt \[[@CR34]\]\< 32 and \> 32\< 1500 and \> 1500low GA, oxygen therapy, frequency of blood transfusions and sepsisChen et al., 2011, USA \[[@CR41]\]\< 30\< 1500low GA, Sepsis, oxygen exposureHadi and Hamdy, 2013, Egypt \[[@CR37]\]\< 32\< 1250low GA, low BW, Ventilation, blood transfusions, sepsis, Patent ductus arteriosus, IVHNair et al., 2001, Oman \[[@CR36]\]\< 32\< 1500low BW, Low GA, TPN*BW* Birth weight, *GA* Gestational age, *PDA* Patent ductus arteriosus, *CPAP* Continuous positive pressure ventilation, *IVH* Intraventricular hemorrhage, *TPN* Total parenteral nutrition

Conclusion {#Sec24}
==========

Finally, it can be concluded that the present systematic review and meta-analysis summarizes the results of previous studies and provides a comprehensive view of ROP in Iran. Although the prevalence of ROP in Iran is similar to some developing countries, it is much higher than some other countries. Therefore, this fact highlights the importance of preventing and treating ROP and its following complications. To achieve a more favorable level and reduce the prevalence in the coming years, screening and close monitoring by experienced ophthalmologists are essential to diagnose and treat the common complications of prematurity and prevent visual impairment or blindness.
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